CoChat

MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy

Open access
Wang, Xiaohai, Li, Wenping, Marcus, Jacob, Pearson, Michelle, Song, Lixin, Smith, Karen, Terracina, Giuseppe, Lee, Julie, Hong, Kwok-Lam Karen, Lu, Sherry X., Hyde, Lynn, Chen, Shu-Cheng, Kinsley, David, Melchor, Jerry P., Rubins, Daniel J., Meng, Xiangjun, Hostetler, Eric, Sur, Cyrille, Zhang, Lili, Schachter, Joel B., Hess, J. Fred, Selnick, Harold G., Vocadlo, David J., McEachern, Ernest J., Uslaner, Jason M., Duffy, Joseph L., Smith, Sean M. · 2020 · The Journal of Pharmacology and Experimental Therapeutics
Cited by 79

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Deposition of hyperphosphorylated and aggregated tau protein in the central nervous system is characteristic of Alzheimer disease and other tauopathies. Tau is subject to O -linked N -acetylglucosamine ( O -GlcNAc) modification, and O -GlcNAcylation of tau has been shown to influence tau phosphorylation and aggregation. Inhibition of O -GlcNAcase (OGA), the enzyme that removes O -GlcNAc moieties, is a novel strategy to attenuate the formation of pathologic tau. Here we described the in vitro and in vivo pharmacological properties of a novel and selective OGA inhibitor, MK-8719. In vitro, this compound is a potent inhibitor of the human OGA enzyme with comparable activity against the corresponding enzymes from mouse, rat, and dog. In vivo, oral administration of MK-8719 elevates brain and peripheral blood mononuclear cell O -GlcNAc levels in a dose-dependent manner. In addition, positron emission tomography imaging studies demonstrate robust target engagement of MK-8719 in the brains of rats and rTg4510 mice. In the rTg4510 mouse model of human tauopathy, MK-8719 significantly increases brain O -GlcNAc levels and reduces pathologic tau. The reduction in tau pathology in rTg4510 mice is accompanied by attenuation of brain atrophy, including reduction of forebrain volume loss as revealed by volumetric magnetic resonance imaging analysis. These findings suggest that OGA inhibition may reduce tau pathology in tauopathies. However, since hundreds of O -GlcNAcylated proteins may be influenced by OGA inhibition, it will be critical to understand the physiologic and toxicological consequences of chronic O -GlcNAc elevation in vivo. SIGNIFICANCE STATEMENT MK-8719 is a novel, selective, and potent O -linked N- acetylglucosamine ( O -GlcNAc)-ase (OGA) inhibitor that inhibits OGA enzyme activity across multiple species with comparable in vitro potency. In vivo, MK-8719 elevates brain O -GlcNAc levels, reduces pathological tau, and ameliorates brain atrophy in the rTg4510 mouse model of tauopathy. These findings indicate that OGA inhibition may be a promising therapeutic strategy for the treatment of Alzheimer disease and other tauopathies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1124/jpet.120.266122

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 79

Metadata

Authors
Wang, X., Li, W., Marcus, J., Pearson, M., Song, L., Smith, K., Terracina, G., Lee, J., Hong, K.-L. K., Lu, S. X., Hyde, L., Chen, S.-C., Kinsley, D., Melchor, J. P., Rubins, D. J., Meng, X., Hostetler, E., Sur, C., Zhang, L., Schachter, J. B., Hess, J. F., Selnick, H. G., Vocadlo, D. J., McEachern, E. J., Uslaner, J. M., Duffy, J. L., & Smith, S. M.
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
2020-08
Volume
374
Issue
2
Pages
252-263
ISSN
0022-3565 (ISSN-L)
OpenAlex
W3031176037
Cited by
79
References
15
FWCI
5.66
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy. https://app.cochat.ai/papers/10.1124/jpet.120.266122
The paper
Wang, X., Li, W., Marcus, J., Pearson, M., Song, L., Smith, K., Terracina, G., Lee, J., Hong, K.-L. K., Lu, S. X., Hyde, L., Chen, S.-C., Kinsley, D., Melchor, J. P., Rubins, D. J., Meng, X., Hostetler, E., Sur, C., Zhang, L., . . . Smith, S. M. (2020). MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.120.266122

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.